Whilst we recognise that the demonstration of effect in a more high-grade serous cancer cell line such as OVSAHO or OVCAR 8 would add to the case for clinical trials of this treatment in patients with ovarian cancer, the evidence of effect in SKOV3 cells, which express high levels of 5T4, but are thought to represent a clear cell/endometrioid phenotype, support using 5T4 expression as an inclusion criterion in future trials, over histotype alone. Here, TPBG is linked to ovarian carcinoma.